Curaleaf Keeps Aurora Bid Open After Rival Organigram Deal

Curaleaf Holdings announced on November 3, 2026 that its enhanced takeover offer for Aurora Cannabis (ACB ) remains outstanding after Aurora agreed to a competing acquisition by Organigram Global (OGI ). The rival transaction offers C$7.80 per Aurora common share and values Aurora at approximately C$561 million on a fully diluted equity basis.

Organigram and Aurora’s joint announcement says both companies’ boards unanimously approved their arrangement. The companies calculate that the consideration represents a 21% premium to the implied value of Curaleaf’s amended bid as of November 2, 2026, using Curaleaf’s 20-day volume-weighted average share price and a 20-trading-day average USD/CAD exchange rate of 1.4115.

Curaleaf said it is studying the signed rival transaction and argued that its own offer provides better value, a stronger capital-markets profile, greater certainty and speed to close, and greater anticipated synergies. It is seeking details including any break fee, future management and board composition, and any investor rights granted to BAT, a wholly owned indirect subsidiary of British American Tobacco. Curaleaf also criticized the joint announcement for not addressing whether the transaction would be accretive or dilutive.

Two Different Consideration Packages

Aurora shareholders may elect to receive the Organigram consideration entirely in cash, as 5.8626 Organigram common shares per Aurora share, or as C$3.75 in cash plus 3.0431 Organigram shares. The elections are subject to proration and aggregate cash and share caps, so shareholders’ preferred form of consideration is not assured.

Curaleaf’s October 6, 2026 offer notice instead provides US$1.00 in cash plus 0.4013 of a Curaleaf subordinate voting share for each Aurora share. A cap mechanism reduces the number of Curaleaf shares issued if necessary to limit the total consideration to US$6.00 per Aurora share. The offer is open until 11:59 p.m. Mountain Time on December 4, 2026, unless extended, accelerated or withdrawn under its terms.

Curaleaf’s October 5, 2026 announcement assigned its package an implied value of US$5.00 per Aurora share using Curaleaf’s October 2, 2026 closing price and stated exchange-rate assumption. That is a dated implied value for a predominantly stock-based package, not a fixed cash price. Organigram’s all-cash election is fixed at its headline price before proration, while its share-containing elections depend on Organigram’s share value. The two bidders’ headline amounts also use different currencies.

Financing and Competing Synergy Estimates

Organigram and Aurora project more than C$50 million of identified synergies from cross-selling, procurement scale, consolidated distribution, public-company expenses and routing international demand across the combined production network. Curaleaf separately projects at least US$40 million of annual cost synergies from its proposed combination. Those estimates belong to different transaction structures and currencies, making them unsuitable for a direct numerical comparison.

The companies expect the Organigram transaction’s cash component to be funded with cash on hand, the concurrent BAT investment and an increase in Organigram’s existing credit facility. BAT agreed to buy 141.0 million Organigram shares at C$1.33 each for gross proceeds of £100 million, stated as C$187.5 million using the November 2 exchange rate. Non-voting convertible preferred shares would be issued to the extent common-share issuance would take BAT above its 30% ownership threshold.

ATB Financial supplied a fully committed and underwritten package of up to $210 million in senior secured credit facilities. BAT also has the right to nominate up to 30% of Organigram’s board, subject to maintaining specified ownership thresholds. Amendments to its preemptive and top-up rights remain to be negotiated before the private placement and acquisition close.

Approval Timetable and Diligence Dispute

Curaleaf alleges that Aurora granted Organigram due-diligence access while refusing Curaleaf access and direct engagement, blocking any chance of an enhanced bid and breaching the board’s fiduciary duties.

Aurora’s special committee of independent directors conducted a strategic review that included outreach to multiple parties. Aurora’s board continues to recommend that shareholders reject Curaleaf’s offer and not tender their shares.

Closing the Organigram transaction requires at least two-thirds of votes cast by Aurora shareholders and a separate simple majority excluding certain shareholders. The Organigram share issuance and private placement require a simple majority of Organigram votes, excluding BAT’s shares. Regulatory approvals and approval from the Supreme Court of British Columbia are also required. The companies expect shareholder meetings in December 2026 and completion in January 2027.

The immediate question is whether Curaleaf revises its offer after reviewing the rival agreement and receiving the disclosures it requested. Until then, Aurora has a signed, board-backed transaction with Organigram, but not a completed one, while Curaleaf’s separate cash-and-share bid remains live.